Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 20 mg) |
| Drug Class | Thrombopoietin receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Summary
- Avatrombopag (Doptelet) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and also for those with chronic immune thrombocytopenia who have had an insufficient response to previous treatments.
- A total of 13 systematic reviews/meta-analyses were reviewed, providing insights into the safety and effectiveness of Avatrombopag compared to other drugs within its class.
- The studys generally position Avatrombopag as more effective than similar drugs such as Eltrombopag and Hetrombopag, particularly in adult patients with immune thrombocytopenia (ITP), demonstrating higher overall platelet response rates.
- Evidence supports that Avatromabog maintains its efficacy across different patient groups including those with chronic liver disease scheduled for a procedure and those suffering from chronic immune thromobcytopenia.
- Some studies indicate that older patients or individuals having history of thombosis may be at increased risk when on Throbopoietic agents like avotrambag but detailed comparative data on these subgroups remains scarce requiring further investigation.
- In terms of safety profile, it appears comparable if not superior to other TPO-RAs; adverse events reported do not significantly differ from placebo or other TPO-RAs including major concerns such as elevated transaminase levels or thombosis incidents.
- Long-term administration up-to six months suggests favorable safety profile based on adverse event reporting which indicates general safe use over intended time frame without significant increase in any adverse events grade 3/4 AEs, elevated transaminase levels etc.
- The documentation underscores high efficacy alongwith comparably safer profile making it compelling choice however recommends careful consideration around long term usage especially among specific patient subgroups warranting ongoing monitoring & tailored therapeutic strategies based on individual risk factors.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Doptelet (avatrombopag) Prescribing Information. | 2021 | AkaRx, Inc., Durham, NC |